Genetic markers for prediction of treatment outcomes in ovarian cancer

被引：17

作者：

Caiola, E. ^{[1
]}

Broggini, M. ^{[1
]}

Marabese, M. ^{[1
]}

机构：

[1] IRCCS, Ist Ric Farmacol Mario Negri, Dept Oncol, Mol Pharmacol Lab, I-20156 Milan, Italy

来源：

PHARMACOGENOMICS JOURNAL | 2014年 / 14卷 / 05期

关键词：

NUCLEOTIDE EXCISION-REPAIR; CISPLATIN-BASED CHEMOTHERAPY; S-TRANSFERASE POLYMORPHISMS; GYNECOLOGIC-ONCOLOGY-GROUP; PROGRESSION-FREE SURVIVAL; PLATINUM-BASED THERAPY; DRUG-RESISTANCE; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; DNA-REPAIR;

D O I：

10.1038/tpj.2014.32

中图分类号：

Q3 [遗传学];

学科分类号：

071007 [遗传学];

摘要：

Drug resistance in epithelial ovarian cancer (EOC) limits the efficacy of therapies for this malignancy. This phenomenon might be partially explained by strong inter-individual genomic heterogeneity. Single nucleotide polymorphisms (SNPs) located in specific genes involved in platinum-based drugs inactivation and the metabolism and extrusion of taxanes could be relevant in terms of drugs response prediction. In this paper, we review candidates for genetic markers of treatment outcomes in ovarian cancer.. Although an association between SNPs and response to chemotherapy has been detected in several studies, no clear conclusions can be drawn because of conflicting results. Genetic variants in determining response to chemotherapy and clinical outcome need to be clarified in EOC to allow stratification of patients, which would help optimize therapy.

引用

页码：401 / 410

页数：10

共 67 条

[1]

Allen JD, 2000, CANCER RES, V60, P5761

[2]

A map of human genome variation from population-scale sequencing [J].

Altshuler, David ;

Durbin, Richard M. ;

Abecasis, Goncalo R. ;

Bentley, David R. ;

Chakravarti, Aravinda ;

Clark, Andrew G. ;

Collins, Francis S. ;

De la Vega, Francisco M. ;

Donnelly, Peter ;

Egholm, Michael ;

Flicek, Paul ;

Gabriel, Stacey B. ;

Gibbs, Richard A. ;

Knoppers, Bartha M. ;

Lander, Eric S. ;

Lehrach, Hans ;

Mardis, Elaine R. ;

McVean, Gil A. ;

Nickerson, DebbieA. ;

Peltonen, Leena ;

Schafer, Alan J. ;

Sherry, Stephen T. ;

Wang, Jun ;

Wilson, Richard K. ;

Gibbs, Richard A. ;

Deiros, David ;

Metzker, Mike ;

Muzny, Donna ;

Reid, Jeff ;

Wheeler, David ;

Wang, Jun ;

Li, Jingxiang ;

Jian, Min ;

Li, Guoqing ;

Li, Ruiqiang ;

Liang, Huiqing ;

Tian, Geng ;

Wang, Bo ;

Wang, Jian ;

Wang, Wei ;

Yang, Huanming ;

Zhang, Xiuqing ;

Zheng, Huisong ;

Lander, Eric S. ;

Altshuler, David L. ;

Ambrogio, Lauren ;

Bloom, Toby ;

Cibulskis, Kristian ;

Fennell, Tim J. ;

Gabriel, Stacey B. .

NATURE, 2010, 467 (7319) :1061-1073

[3]

Assis J, 2013, INT J CLIN EXP MED, V6, P552

[4]

Baekelandt MM, 2000, ANTICANCER RES, V20, P1061

[5]

Bast R C Jr, 2011, Ann Oncol, V22 Suppl 8, pviii5, DOI 10.1093/annonc/mdr516

[6]

Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival [J].

Beeghly, A ;

Katsaros, D ;

Chen, H ;

Fracchioli, S ;

Zhang, Y ;

Massobrio, M ;

Risch, H ;

Jones, B ;

Yu, H .

GYNECOLOGIC ONCOLOGY, 2006, 100 (02) :330-337

[7]

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer [J].

Bergmann, Troels K. ;

Green, Henrik ;

Brasch-Andersen, Charlotte ;

Mirza, Mansoor R. ;

Herrstedt, Jorn ;

Holund, Berit ;

du Bois, Andreas ;

Damkier, Per ;

Vach, Werner ;

Brosen, Kim ;

Peterson, Curt .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (07) :693-700

[8]

Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy [J].

Boesmueller, Hans ;

Haitchi-Petnehazy, Sophie ;

Webersinke, Gerald ;

Marschon, Renate ;

Roithmeier, Franz ;

Stummvoll, Wolfgang ;

Fehm, Tanja ;

Klier-Richter, Margit ;

Bonzheim, Irina ;

Staebler, Annette ;

Fend, Falko .

VIRCHOWS ARCHIV, 2011, 459 (02) :183-191

[9]

Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC) [J].

Bolton, K. L. ;

Ganda, C. ;

Berchuck, A. ;

Pharaoh, P. D. P. ;

Gayther, S. A. .

JOURNAL OF INTERNAL MEDICINE, 2012, 271 (04) :366-378

[10]

Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters [J].

Brauch, Hiltrud ;

Schroth, Werner ;

Goetz, Matthew P. ;

Muerdter, Thomas E. ;

Winter, Stefan ;

Ingle, James N. ;

Schwab, Matthias ;

Eichelbaum, Michel .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :176-180

← 1 2 3 4 5 6 7 →